This indicates that the triggers of complement activation in human NASH are strong and persistent, and suggests that the downregulation of factor H combined with the local increase in properdin overwhelm the inhibitory effects of DAF. The gene discussed is CFP; the disease is metabolic dysfunction-associated steatohepatitis.